Results 191 to 200 of about 30,048 (219)

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin   +11 more
wiley   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Production, maintenance and resource scheduling: A review

European Journal of Operational Research, 2023
M Geurtsen   +2 more
exaly  

Home - About - Disclaimer - Privacy